PO.6.132 A phase 2b study of afimetoran (BMS-986256) in patients with active systemic lupus erythematosus (SLE): optimization of a lupus clinical trial design

• S Banerjee,
• V Shah,
• M Harrison,
• Y Shen,
• JT Merrill,
• U Ranganathan,
• MK Crow,
• N Delev,
• D Grasela,
• E Culotta,
• S Greenberg

Affiliations

S Banerjee

Paediatric Department, Bedford Hospital NHS Trust, Bedford, UK

V Shah

1Radiology and Biomedical Imaging, UCSF, San Francisco, CA

M Harrison

Division of Clinical Sciences, Imperial College London, London, UK

Y Shen

3School of Public Health, University of Alberta, Edmonton, Canada

JT Merrill

1Oklahoma Medical Research Foundation, Clinical Pharmacology, Oklahoma, USA

U Ranganathan

1Bristol Myers Squibb ~ Lawrenceville, NJ ~ USA

MK Crow

3Hospital for Special Surgery, Mary Kirkland Center for Lupus Research ~ New York, NY ~ USA

N Delev

1Bristol Myers Squibb ~ Lawrenceville, NJ ~ USA

D Grasela

1Bristol Myers Squibb ~ Lawrenceville, NJ ~ USA

E Culotta

1Bristol Myers Squibb ~ Lawrenceville, NJ ~ USA

S Greenberg

1Bristol Myers Squibb ~ Lawrenceville, NJ ~ USA